Yisheng Biopharma and the United States Army Medical Research Institute of Infectious Diseases Announce Positive Animal Results of Vaccine Against Ebola Virus
PRNewswire/ -- Yisheng Biopharma Co., Ltd. ("Yisheng Biopharma"), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of biological vaccines and pharmaceutical products, and the United States Army Medical Research Institute of Infectious Diseases ("USAMRIID") today announced preliminary positive animal results of a virus-like particle (VLP)-based vaccine in combination with PIKA adjuvant, a Toll-Like Receptor 3 (TLR3) agonist. This study was conducted by the scientists at USAMRIID under the cooperative partnership between the two institutions. The Ebola VLP vaccine was developed by USAMRIID and PIKA is a proprietary product from Yisheng Biopharma.
Fisher Center Scientists Create a Novel Imaging Technology Allowing the 3D Visualization of Brain Defects That Cause Alzheimer's Disease
As published in the scientific journal Cell Reports, under the direction of Dr. Paul Greengard, Dr. Marc Tessier-Lavigne, and spearheaded by Dr. Marc Flajolet, Fisher Center scientists created technology that allows the visualization of amyloid plaques as well as other Alzheimer's hallmarks, such as tau, vasculature and microglia activation, in a large volume, in an entire mouse brain with the potential application of frozen human brain samples."We are proud that the funding we provide has resulted in innovative, never before seen imaging of what causes Alzheimer's disease," said Kent L. Karosen, President/CEO Fisher Center for Alzheimer's Research Foundation. The Fisher Center scientists are working diligently to better understand the cause and cure of the disease and with the ability to visualize the causes of Alzheimer's, we're one step closer to a cure."
REVLIMID® (Lenalidomide) Approved by the European Commission for the Treatment of Relapsed/Refractory Patients with Mantle Cell Lymphoma
BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that the European Commission (EC) has approved REVLIMID® (lenalidomide) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
Granted patent with number US 9,403,906 B1 planned to be published August 2, 2016, concerns Cantargias method to utilize IL1RAP as a target molecule for the treatment of several types of solid tumors. The patent provides protection until 2032 and covers treatment of several common forms of solid tumors, such as breast cancer, colon cancer, lung cancer and malignant melanoma.
PENTAX Medical Introduces New High Definition Video Processor for Gastrointestinal Endoscopic Imaging
HAMBURG, Germany--(BUSINESS WIRE)--PENTAX Medical launches into Europe, Middle East and Africa a new high definition (HD) video processor for highly detailed endoscopic imaging of the gastrointestinal tract. The new DEFINA GI EPK-3000 performance system combines advanced HD imaging with i-scan image processing to cost effectively deliver excellence in image quality. This enhanced endoscopic in vivo diagnostic ensures faster detection, easier demarcation and characterization of gastrointestinal lesions to support improved patient outcomes.
Sartorius Acquires U.S. Start-up ViroCyt
• Acquisition expands bioanalytical portfolio of Lab Products & Services division • Specialist for virus quantification significantly speeds up R&D and time to clinic in virology GOETTINGEN, Germany--(BUSINESS WIRE)--Sartorius, a leading international pharmaceutical and laboratory tools provider, today announced the acquisition of ViroCyt Incorporated, an innovator in the field of rapid virus quantification. Based in Broomfield, Colorado, USA, the start-up is expected to achieve high double-digit growth and to generate more than million sales revenues in 2016 while achieving break even underlying EBITDA by the end of 2018. The transaction values ViroCyt at approx. million.
The U.S. Food and Drug Administration released a draft guidance document
Today, the U.S. Food and Drug Administration released a draft guidance document, "Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product." This draft guidance is a “how-to” guide to supplement previously released final guidance “In Vitro Companion Diagnostic Devices,” which defined in vitro companion diagnostic devices (IVD companion diagnostics) and set the expectation that IVD companion diagnostics and corresponding therapeutic products should be approved or cleared by the FDA at the same time